title: Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis.
abstract: David Dowdy and colleagues discuss the complexities of costing new TB diagnostic tests, including GeneXpert, and argue that flexible analytic tools are needed for decision-makers to adapt large-sample cost-effectiveness data to local conditions.
authors.affiliation: Department of Medicine, University of California, San Francisco, California, United States of America. ddowdy@jhsph.edu
authors.forename: David W
authors.initials: DW
authors.lastname: Dowdy
authors.forename: Adithya
authors.initials: A
authors.lastname: Cattamanchi
authors.forename: Karen R
authors.initials: KR
authors.lastname: Steingart
authors.forename: Madhukar
authors.initials: M
authors.lastname: Pai
mesh_terms: D003362:Cost-Benefit Analysis; D005189:False Positive Reactions; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000191:economics*; D009169:Mycobacterium tuberculosis / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction / Q000191:economics*; D012680:Sensitivity and Specificity; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000382:microbiology